> For the complete documentation index, see [llms.txt](https://help.bioinsight.illumina.com/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://help.bioinsight.illumina.com/emedgene/emedgene-analyze-manual/tertiary-analysis-pipeline/str_calling_and_interpretation/str-loci-considered-by-ai-shortlist.md).

# STR loci considered by AI Shortlist

Variant calling reliability and availability of meaningful annotations for STR loci can vary. AI Shortlist considers STR variants only in the Emedgene-curated subset of genes. The subset is defined by gene, not by genomic region.

STRs that are not tagged by AI Shortlist are still included in the analysis. AI Shortlist does not prioritize them, but they remain available for manual review and tagging.

For each gene that AI Shortlist considers for STR variants, Table 1 shows the disease-associated locus, the associated conditions, the inheritance mode, and the repeat unit, from the gnomAD catalog of known disease-associated STR loci.

{% hint style="info" %}
For information on STR variants calling, filtering, and prioritization, see [Tertiary analysis of STR variants](https://help.bioinsight.illumina.com/emedgene/emedgene-analyze-manual/tertiary-analysis-pipeline/str_calling_and_interpretation.md).
{% endhint %}

**Table 1. Genes considered by AI Shortlist for STR variants.**

<table data-header-hidden="false" data-header-sticky data-full-width="true"><thead><tr><th width="43" data-type="number">№</th><th width="110">Gene</th><th width="264">Disease-associated locus (GRCh38)</th><th>Associated condition(s)</th><th width="122">Inheritance mode</th><th width="100">Repeat unit</th></tr></thead><tbody><tr><td>1</td><td><em>AR</em></td><td>X:67545316-67545385</td><td>Spinal and bulbar muscular atrophy (SBMA)</td><td>XR</td><td>GCA</td></tr><tr><td>2</td><td><em>ATN1</em></td><td>12:6936716-6936773</td><td>Dentatorubral-pallidoluysian atrophy (DRPLA)</td><td>AD</td><td>CAG</td></tr><tr><td>3</td><td><em>ATXN1</em></td><td>6:16327633-16327723</td><td>Spinocerebellar ataxia 1 (SCA1)</td><td>AD</td><td>TGC</td></tr><tr><td>4</td><td><em>ATXN10</em></td><td>22:45795354-45795424</td><td>Spinocerebellar ataxia 10 (SCA10)</td><td>AD</td><td>ATTCT</td></tr><tr><td>5</td><td><em>ATXN2</em></td><td>12:111598949-111599018</td><td>Spinocerebellar ataxia 2 (SCA2)</td><td>AD</td><td>GCT</td></tr><tr><td>6</td><td><em>ATXN3</em></td><td>14:92071010-92071040</td><td>Spinocerebellar ataxia 3 (SCA3)</td><td>AD</td><td>CTG</td></tr><tr><td>7</td><td><em>ATXN7</em></td><td>3:63912684-63912714</td><td>Spinocerebellar ataxia 7 (SCA7)</td><td>AD</td><td>GCA</td></tr><tr><td>8</td><td><em>ATXN8OS</em></td><td>13:70139383-70139428</td><td>Spinocerebellar ataxia 8 (SCA8)</td><td>AD</td><td>CTG</td></tr><tr><td>9</td><td><em>C9ORF72</em></td><td>9:27573528-27573546</td><td>Frontotemporal dementia and/or amyotrophic lateral sclerosis 1 (FTDALS1)</td><td>AD</td><td>GGCCCC</td></tr><tr><td>10</td><td><em>CACNA1A</em></td><td>19:13207858-13207897</td><td>Spinocerebellar ataxia 6 (SCA6)</td><td>AD</td><td>CTG</td></tr><tr><td>11</td><td><em>CNBP</em></td><td>3:129172576-129172656</td><td>Myotonic dystrophy 2 (DM2)</td><td>AD</td><td>CAGG</td></tr><tr><td>12</td><td><em>DMPK</em></td><td>19:45770204-45770264</td><td>Myotonic dystrophy 1 (DM1)</td><td>AD</td><td>CAG</td></tr><tr><td>13</td><td><em>FMR1</em></td><td>X:147912050-147912110</td><td>Fragile X syndrome (FXS); Fragile X tremor/ataxia syndrome (FXTAS)</td><td>XD</td><td>CGG</td></tr><tr><td>14</td><td><em>FXN</em></td><td>9:69037286-69037304</td><td>Friedreich ataxia (FRDA)</td><td>AR</td><td>GAA</td></tr><tr><td>15</td><td><em>HTT</em></td><td>4:3074876-3074933</td><td>Huntington disease (HD)</td><td>AD</td><td>CAG</td></tr><tr><td>16</td><td><em>JPH3</em></td><td>16:87604287-87604329</td><td>Huntington disease-like 2 (HDL2)</td><td>AD</td><td>CTG</td></tr><tr><td>17</td><td><em>NOP56</em></td><td>20:2652733-2652757</td><td>Spinocerebellar ataxia 36 (SCA36)</td><td>AD</td><td>GGCCTG</td></tr><tr><td>18</td><td><em>PPP2R2B</em></td><td>5:146878727-146878757</td><td>Spinocerebellar ataxia 12 (SCA12)</td><td>AD</td><td>GCT</td></tr><tr><td>19</td><td><em>TBP</em></td><td>6:170561906-170562017</td><td>Spinocerebellar ataxia 17 (SCA17)</td><td>AD</td><td>GCA</td></tr></tbody></table>

***

## Learn more

<table data-view="cards"><thead><tr><th></th><th></th><th></th></tr></thead><tbody><tr><td><strong>Tertiary analysis of STR variants</strong></td><td>How STR variants are called, filtered, annotated, and prioritized.</td><td><i class="fa-arrow-up-right-from-square">:arrow-up-right-from-square:</i> <a href="https://help.bioinsight.illumina.com/emedgene/emedgene-analyze-manual/tertiary-analysis-pipeline/str_calling_and_interpretation.md">Learn more</a></td></tr><tr><td><strong>STR loci annotated with gnomAD pathogenicity data</strong></td><td>The gnomAD loci that Emedgene annotates, with the repeat-count range for each significance class.</td><td><i class="fa-arrow-up-right-from-square">:arrow-up-right-from-square:</i> <a href="https://help.bioinsight.illumina.com/emedgene/emedgene-analyze-manual/tertiary-analysis-pipeline/str_calling_and_interpretation/str-loci-annotated-with-gnomad-pathogenicity-data.md">Learn more</a></td></tr></tbody></table>


---

# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.

## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation by asking a question.

Perform an HTTP GET request on the following URL with the `ask` and `goal` query parameters:

```
GET https://help.bioinsight.illumina.com/emedgene/emedgene-analyze-manual/tertiary-analysis-pipeline/str_calling_and_interpretation/str-loci-considered-by-ai-shortlist.md?ask=<question>&goal=<user_goal>
```

`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is what the user is ultimately trying to achieve, the reason they need the answer. Sharing it helps GitBook give you a better, more relevant answer. A goal is most helpful when it describes the outcome the user wants rather than restating the question. For example, with `ask=how do I create an API token`, a goal like `automate deployments from our CI pipeline` lets GitBook tailor the answer to that use case.

The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.
